Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 14.

Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Frangenberg, A., Bernschein, A., Gardizi, M., Meyer, M., Schnittner, U., Hatwig, R. and Wolf, J. (2014). How tumor board recommendations influence patient care: Adherence to clinical decisions made in multidisciplinary teams. Oncol. Res. Treat., 37. S. 105 - 107. BASEL: KARGER. ISSN 2296-5262

Gautschi, O., Pall, G., Schultheis, A., Keller, F. Aebersold, Gardizi, M., Heuckmann, J., Merkelbach-Bruse, S., Diebold, J., Wolf, J. and Heukamp, L. (2014). LUNG ADENOCARCINOMA WITH RET FUSION: EARLY EXPERIENCE WITH DIAGNOSIS AND TARGETED THERAPY. J. Thorac. Oncol., 9 (4). S. S38 - 1. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1556-1380

Michels, S., Gardizi, M., Schultheis, A., Scheffler, M., Karachaliou, N., Teixido, C., Heukamp, L., Merkelbach-Bruse, S., Thurat, M., Nogova, L., Bos, M., Mattonet, C., Grohe, C., Sebastian, M., Thomas, M., Reck, M., Stahel, R., Pirker, R., Zoechbauer-Mueller, S., Groen, H., Dingemanns, A. -M, Smit, E., Thomas, R., Buettner, R., Massuti, B., Rosell, R. and Wolf, J. (2014). EUCROSS: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J. (2017). Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center. Oncol. Res. Treat., 40. S. 137 - 139. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Buettner, R., Elter, T., Toepelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T. and Wolf, J. (2014). MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Nogova, L., Papachristou, I., Persigehl, T., Dietlein, F., Zander, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 131 - 132. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Nogova, L., Michels, S., Woempner, C., Persigehl, T. and Wolf, J. (2014). BARIS: A phase I trial to evaluate the safety and tolerability of combined nintedanib and everolimus in solid tumors and to determine the maximum tolerated dose (MTD) of the combination. Oncol. Res. Treat., 37. S. 155 - 156. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Michels, S., Gardizi, M., Koenig, K., Merkelbach-Bruse, S., Stamm, K., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). DDR2 mutations in non-small cell lung cancer (NSCLC): clinical, histological and genetic characteristics. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Mar 28 12:39:19 2024 CET.